The Trump–Novo Nordisk Deal: $245/mo Ozempic and What It Means for You
In November 2025, the White House announced a pricing arrangement with Novo Nordisk and Eli Lilly that brought branded GLP-1 medications down to roughly $245/month for eligible Medicare/Medicaid beneficiaries, plus a TrumpRx cash-pay program launching January 2026. Here's what it actually changed, who qualifies, and how it stacks up against compounded options.
The verified facts
- Date announced: November 6, 2025 (White House Fact Sheet).
- Drugs covered: branded Ozempic and Wegovy (Novo Nordisk) and Mounjaro and Zepbound (Eli Lilly).
- Eligible patients: Medicare and Medicaid beneficiaries with documented qualifying conditions; plus TrumpRx cash-pay enrollees beginning January 2026.
- Headline price: ~$245/month for eligible Medicare/Medicaid; TrumpRx cash launched at ~$350/month with a 24-month glide path toward $245.
- Source verification: White House Fact Sheet 2025-11; CNBC coverage 2025-11-06; AJMC; Healio.
Who actually qualifies for the $245 price
The qualifying paths in May 2026 are:
- Medicare beneficiaries with a documented qualifying condition. For Ozempic, this is typically type 2 diabetes. For Wegovy, this is chronic weight management with a documented comorbidity (BMI ≥30, or BMI ≥27 with hypertension/dyslipidemia/T2D).
- Medicaid beneficiaries in states that have aligned with the federal pricing structure. Implementation varies by state.
- TrumpRx cash-pay enrollees: launched January 2026 at ~$350/month for branded GLP-1, with the deal terms specifying a 24-month progression toward $245/month. As of May 2026, cash price is in the $300-$350 range depending on supplier.
Patients on private commercial insurance plans typically still see the standard list price minus their plan's negotiated discount and prior-auth approval — the Trump–Novo deal does not directly alter commercial insurance pricing.
How the price compares with NHWL's compounded program
Cash equivalent monthly cost across pathways (May 2026):
- Branded Ozempic / Wegovy without insurance: ~$968-$1,349/month (list price)
- TrumpRx cash: ~$300-$350/month (current, trending toward $245)
- Medicare/Medicaid with deal pricing: ~$245/month
- NHWL compounded semaglutide (90-day program): $166/month equivalent
- NHWL compounded tirzepatide (90-day program): $233/month equivalent
For uninsured cash-pay patients, NHWL compounded semaglutide remains roughly 32% lower than the TrumpRx target. For Medicare/Medicaid eligibles, the gap is closer — about $79/month for semaglutide. For tirzepatide, the prices are roughly comparable.
When the Trump–Novo path is the better choice
- You have Medicare or Medicaid coverage with the deal pricing applied.
- You specifically need an FDA-approved finished product (clinical trial enrollment, employer benefit requirements, etc.).
- Your physician has a clinical reason to prefer branded over compounded (e.g., specific allergy to a compounding excipient).
- You travel internationally frequently and prefer commercial packaging documentation.
When NHWL's compounded path remains the better choice
- You're uninsured cash-pay and the $166-$233/month cost is meaningfully lower than $245-$350/month.
- You want individualized dose titration that the brand-name pen's fixed step doses don't support.
- You want B12 / lipotropic add-ons in the same protocol.
- You want bundled physician oversight (initial visit + ongoing labs + dose adjustments) without separate office-visit fees.
What we tell our patients honestly
If you have Medicare or Medicaid and qualify for the $245 branded price, that may be the right path. Bring it up at the consultation. We'd rather refer you to that path than charge you for compounded therapy that's only marginally cheaper for your specific situation.
If you're cash-pay and the TrumpRx pricing is still meaningfully more than our compounded program, the math typically favors compounded. We'll walk through the comparison in detail during the visit.
Frequently asked questions
What is the Trump–Novo Nordisk deal?
A November 2025 pricing arrangement that makes branded Ozempic and Wegovy available at approximately $245/month for eligible Medicare and Medicaid beneficiaries, plus the TrumpRx cash-pay program launching January 2026 starting at ~$350/month and trending toward $245 over 24 months. Mounjaro and Zepbound from Eli Lilly were covered under similar terms.
Who qualifies for the $245 price?
Medicare and Medicaid beneficiaries with documented qualifying conditions (type 2 diabetes for Ozempic; chronic weight management with comorbidity for Wegovy). TrumpRx cash-pay enrollees qualify for the cash-pay tier starting at ~$350/month. Commercial-insurance patients typically still see standard pricing minus plan negotiation.
Is $245/mo cheaper than compounded semaglutide at NHWL?
No. NHWL compounded semaglutide is $166/month equivalent (90-day program at $499) — about 32% lower than the $245 TrumpRx target. For tirzepatide, our $233/month is comparable.
Should I switch from compounded to branded TrumpRx?
It depends on coverage. If you have Medicare/Medicaid with $245/mo effective pricing, the switch may be worth considering. If you're cash-pay, compounded is typically still cheaper. We help patients evaluate honestly.
Does the deal affect compounded GLP-1 legality?
No. It's a pricing arrangement, not a regulatory action. The April 30, 2026 FDA proposal on 503B Bulks affects only 503(b) outsourcing — not the 503(a) patient-specific pathway under which NHWL operates.
This article is informational only and not medical or financial advice. Pricing and availability are current as of May 10, 2026 and may change. Source citations: White House Fact Sheet 2025-11-06; CNBC 2025-11-06; AJMC; Healio. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by these companies. Compounded medications are not FDA-approved finished products.